PET (positron emission tomography) for Alzheimer's on April agenda at CMS (Centers for Medicare and Medicaid Services):
This article was originally published in Clinica
Executive Summary
The Centers for Medicare & Medicaid Services has scheduled an expert panel meeting with the National Institute on Aging on April 5-6 to review the use of positron emission tomography in diagnosing Alzheimer's disease. The information will be used to assess a request that CMS pay for PET to distinguish patients with Alzhemier's disease from those with other causes or symptoms confounding the diagnosis of dementia. The NIA is currently involved in setting up a major study assessing whether magnetic resonance imaging, PET or any other biomarker could be used as surrogate endpoints in phase 2 and 3 clinical trials for the prevention and treatment of Alzheimer's disease.